|1.||Nakamura, Masataka: 5 articles (12/2014 - 08/2006)|
|2.||Lai, Eseng: 5 articles (11/2009 - 11/2008)|
|3.||Hirai, Hiroyuki: 4 articles (12/2014 - 08/2006)|
|4.||Urade, Yoshihiro: 4 articles (08/2014 - 08/2006)|
|5.||Hori, Masatoshi: 3 articles (12/2014 - 12/2008)|
|6.||Murata, Takahisa: 3 articles (12/2014 - 12/2008)|
|7.||Ozaki, Hiroshi: 3 articles (12/2014 - 12/2008)|
|8.||Aritake, Kosuke: 3 articles (06/2014 - 08/2006)|
|9.||Hutchinson, John H: 3 articles (11/2011 - 08/2009)|
|10.||Bain, Gretchen: 3 articles (11/2011 - 08/2009)|
06/01/2011 - "Lately, a new compound, laropiprant, which selectively antagonizes the prostaglandin 2 (PGD2) receptor responsible for flushing, has been developed. "
07/01/2011 - "A novel formulation with a prostaglandin D2 receptor antagonist (laropiprant) appears to substantially decrease the frequency and intensity of flushing, without affecting the other properties of niacin. "
02/01/2010 - "The role of laropiprant, a type 1 prostaglandin D2 receptor antagonist, is to prevent the flushing caused by nicotinic acid. "
12/01/2009 - "Laropiprant is a highly selective prostaglandin D2 receptor 1 antagonist that mitigates niacin-induced flushing. "
04/01/2009 - "Adjunctive treatment with the PGD2 receptor antagonist laropiprant significantly reduces the incidence and severity of niacin-induced flushing. "
11/01/2009 - "Laropiprant is a prostaglandin D2 receptor 1 antagonist that is being developed in combination with niacin for the treatment of dyslipidemia. "
09/01/2009 - "Flushing symptoms limit the use of niacin as an effective treatment for dyslipidemia; laropiprant, a prostaglandin D2 receptor subtype 1 antagonist, reduces niacin-induced flushing and is being developed in combination with niacin. "
05/01/2009 - "Laropiprant (LRPT), a prostaglandin D2 receptor 1 antagonist shown to reduce niacin-induced flushing symptoms, is being developed in combination with niacin for the treatment of dyslipidemia. "
01/01/2014 - "In a randomized controlled trial of patients with dyslipidemia assigned to either extended release niacin (ERN) alone, ERN combined with the selective prostaglandin D2 receptor subtype 1 inhibitor laropiprant (ERN-L) or placebo, niacin lowered serum phosphorus; however, it is not known if it lowers FGF23 concentrations. "
04/01/2010 - "We performed a post hoc data analysis of serum phosphorus concentrations that had been determined serially (at baseline and weeks 4, 8, 12, 18, and 24) among 1547 patients who had dyslipidemia and were randomly assigned in a 3:2:1 ratio to treatment with extended release niacin (ERN; 1 g/d for 4 weeks and dose advanced to 2 g/d for 20 weeks) combined with the selective prostaglandin D2 receptor subtype 1 inhibitor laropiprant (L; n = 761), ERN alone (n = 518), or placebo (n = 268). "
08/15/2009 - "Novel tricyclic antagonists of the prostaglandin D2 receptor DP2 with efficacy in a murine model of allergic rhinitis."
02/01/2009 - "Prostaglandin D2 (PGD2) has been thought to be a potent mediator involved in allergic rhinitis because PGD2 has been recovered from the nasal lavage fluid of patients with allergic rhinitis after allergen provocation and because PGD2 receptor antagonists relieved nasal allergic symptoms in an animal model of allergic rhinitis. "
11/01/2011 - "Discovery and optimization of a biphenylacetic acid series of prostaglandin D2 receptor DP2 antagonists with efficacy in a murine model of allergic rhinitis."
|4.||Asthma (Bronchial Asthma)
01/01/2014 - "The prostaglandin D2 receptor (PTGDR) gene has been associated to asthma and related phenotypes by linking and association studies. "
03/01/2013 - "The aim of this study was to explore whether prostaglandin D2 receptor (PTGDR) polymorphisms confer susceptibility to asthma. "
01/01/2014 - "The prostaglandin D2 receptor (PTGDR) gene in asthma and allergic diseases."
01/01/2011 - "Role of prostaglandin D2 receptor CRTH2 in sustained eosinophil accumulation in the airways of mice with chronic asthma."
09/01/2009 - "A prostaglandin D2 receptor antagonist modifies experimental asthma in sheep."
12/15/2014 - "A deficiency in the prostaglandin D2 receptor CRTH2 exacerbates adjuvant-induced joint inflammation."
11/01/2013 - "CRTH2 is a prostaglandin D2 receptor that plays an important role in allergic inflammation. "
10/01/2011 - "Distinct roles of prostaglandin D2 receptors in chronic skin inflammation."
07/01/2011 - "Pharmacology of AM211, a potent and selective prostaglandin D2 receptor type 2 antagonist that is active in animal models of allergic inflammation."
01/01/2006 - "Targeting the prostaglandin D2 receptors DP and CRTH2 for treatment of inflammation."
|3.||Niacin (Nicotinic Acid)
|4.||Formyl Peptide Receptors (Formyl Peptide Receptor)
|5.||GTP-Binding Proteins (G-Protein)
|7.||EP2 Subtype Prostaglandin E Receptors
|9.||Prostaglandin H2 Thromboxane A2 Receptors